# Mabvax Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mabvax-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.mabvax.com
- Total disclosed funding: $13M
- Latest round: Series B (Nov 21, 2012)
- Investors on record: 4

## About

Mabvax Therapeutics, Inc. is a biotechnology company focused on developing innovative antibody-based therapies for the treatment of cancer. Its advanced research aims to improve patient outcomes through targeted therapies.Mabvax Therapeutics, Inc. operates as a biotechnology firm specializing in antibody-based cancer therapies. Founded in 2006 and headquartered in San Diego, US, the company underwent a strategic merger with Telik in May 2014, resulting in its public listing. CEO David Hansen leads the organization, continuing the commitment to therapeutic innovation. The company has engaged in a total of 12 deals, raising USD 11.61 mn across its funding rounds, with the latest round occurring in 2014.Mabvax Therapeutics is dedicated to developing targeted antibody-based therapies that specifically address cancer treatment. Their innovative product pipeline includes therapeutic candidates designed to enhance the efficacy of existing treatments and improve patient outcomes. These therapies are aimed at various types of cancer, leveraging advanced technology to create targeted solutions.In the most recent year, 2017, Mabvax Therapeutics reported zero revenue, with an EBITDA loss of USD 17,516,791. The company primarily generates revenue through partnerships and collaborations, though there are currently no reported subscription models or direct sales.Mabvax Therapeutics aims to expand its product offerings by advancing new antibody therapies currently in development. The company is targeting further growth in key markets, particularly in North America and Europe, by 2025. The recent funding round of USD 11.61 mn will be utilized to support the development of these new therapies and facilitate the company's expansion into additional markets. The merger in 2014 with Telik positioned Mabvax for broader market engagement, enhancing its capabilities and reach.

## Funding rounds

- Series B, Nov 21, 2012, $5.3M — Burrill & Company, Numoda Capital Innovations, RTP Global
- Series A, Feb 27, 2008, $8M — GBP Capital

## Investors

- GBP Capital (https://capitalatlas.ai/funds/gbp-capital) — Series A
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series B
- Numoda Capital Innovations — Series B
- RTP Global (https://capitalatlas.ai/funds/rtp-global) — Series B